Effect of *Adiantum Capillus veneris* Linn on an Animal Model of Testosterone-Induced Hair Loss

Maryam Noubarani\(^a\), Hossein Rostamkhani\(^b\), Mohammad Erfan\(^b\), Mohammad Kamalinejad\(^b\), Mohammad Reza Eskandari\(^b\), Mohammad Babaieian\(^b\) and Jamshid Salamzadeh\(^a*\)

\(^a\)Department of Pharmacology and Toxicology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran . 
\(^b\)School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**Abstract**

Androgenetic alopecia is the most common form of hair loss in men. The present study was designed to evaluate the hair growth-promoting activity of a preparation of the *Adiantum capillus-veneris* Linn. (*A. capillus-veneris*) on albino mice using a testosterone-induced alopecia model. Five groups of albino mice were studied: (A) Testosterone solution only (n=6); (B) Testosterone + Finasteride solution (2%) (n=6); (C) Testosterone + vehicle (n=6); (D) Testosterone + *A. capillus-veneris* solution (1%) (n=6); (E) intact control (n=2, without testosterone). Alopecia was induced in all intervention groups by testosterone 1.0 mg subcutaneous. *A. capillus-veneris* solution was applied topically to the back skin of animals in the respective group. Hair growth was evaluated by visual observation and histological study of several skin sections via various parameters as follicle density (number of follicles/mm) and anagen/telogen ratio. After 21 days, a patch of diffuse hair loss was seen in animals received testosterone while animals treated with *A. capillus-veneris* showed less hair loss as compared to those treated with testosterone only. The follicular density observed in the *A. capillus-veneris*-treated group was 1.92 ± 0.47, compared to 1.05 ± 0.21 in testosterone-group and 2.05 ± 0.49 in finasteride-treated animals. Anagen/telogen ratio was significantly affected by *A. capillus-veneris*, which was 0.92 ± 0.06 as compared with 0.23 ± 0.03 and 1.12 ± 0.06 for testosterone and finasteride treated groups, respectively. According to visual observation and quantitative data (follicular density and anagen/telogen ratio), *A. capillus-veneris* was found to possess good activity against testosterone-induced alopecia.

**Keywords:** *Adiantum capillus-veneris* linn; Anderogenetic alopecia; Testosterone; Hair growth.

**Introduction**

Androgenetic alopecia or simply “balding”, the most common form of hair loss in men, involves the progressive hair loss, in response to circulating androgens. It may also occur in women (1). Although, there is racial variation in the incidence of androgenetic alopecia, it affects at least 50% of men by the age of 50 years, and up to 70% of all males in later life (2). Prevalence in women has wide variation ranging from six percent in women aged under 50 years to 30-40% of women aged >70 years (3). Treatment of androgenetic alopecia has been one of the major concerns for cosmetologists...
and dermatologists. Over the centuries, a wide range of remedies have been suggested for androgenetic alopecia and currently treatments include wigs and hairpieces, surgery, hormone action modifiers, and non-hormonal therapy. Pharmacological therapies are based on understanding of the mechanism of action of androgen in hair follicle (4). Although, only Minoxidil and Finasteride currently have US Food and Drug Administration (FDA)–approval for treatment of androgenetic alopecia, however, because of adverse reactions, their usage is limited (5). Use of natural products has been quiet common in hair care industry and the search for natural products is being continuously promoted (6). Hair growth-promoting effects of Abru precatorius (7), Cuscuta reflexa (8), Citrullus colocynthis (9) and Eclipta alba (10) was previously reported in different studies. Adiantum is one of the herbs with the traditional claims of hair growth promotion in topical use (11). Adiantum is a large genus of ferns which are widely distributed throughout the world. Amongst the nine species of this plant, Adiantum capillus-veneris Linn. (A. capillus-veneris Linn) is the only species found in Iran (12, 13). Adiantum capillus-veneris has been shown to exhibit antifungal (14), antibacterial (15), antiviral (16) anti-inflammatory, anti-nociceptive (17) and antioxidant activities (18). It is an important drug in ancient literature of Unani system of medicine which has widely been used in patients with urolithiasis and its decoction was claimed to have litholytic activity by several Unani physicians (19). According to the claims in Iranian traditional medicine confirming hair growth promotion by A. capillus-veneris, the present investigation was carried out to evaluate effect, using a pre-clinical experimental testosterone-induced alopecia applying an animal model.

Experimental

Plant material and Extraction

Dried arial parts of the plant A. capillus-veneris were purchased from the local market in Tehran, Iran. This plant is collected from the forest of Northern Iran provinces, Gilan and Mazandaran, during May to June. A botanist approved the taxonomy of plant and confirmed its species. The dried plant was powdered and extracted with maceration in ethanol (95% v/v). The extract was freed from the solvent under vacuum in a rotary evaporator. The yield of the ethanolic extract was 3% w/w.

Animals

The protocol for experimentation was approved by the Institutional Animal Ethics Committee of Shahid Beheshti University of Medical Sciences (Tehran, Iran). Male albino mice (2–3 months) were kept in cages at the room temperature and fed with food and water.

Sample preparation

The ethanol extracts of A. capillus-veneris were incorporated into solution in concentration of 1% (w/v). Solution was made with ethanol base and adding propylene glycol in proportion of 90:10. The extract was then incorporated into prepared solution.

Testosterone test solution

Testosterone solution was prepared as a suspension in the vehicle (ethanol/propllyenglycol 90:10).

Finasteride solution

The 2% standard finasteride solution was prepared in vehicle (ethanol/propllyenglycol, 90:10).

Treatments and animals for study

The method reported by Matias et al. (20) was followed with slight modification. A similar procedure was used by Pandit et al. (8) and Dhanotia et al. (9). In brief, twenty six adult male albino mice 2–3 months of age were randomly allocated in five groups of six animals per group (except group E with two mice). The various groups were treated as follows: (A) Testosterone solution only; (B) Testosterone + Finasteride solution (2%); (C) Testosterone + vehicle; (D) Testosterone + A. capillus-veneris solution (1%); (E) intact control (without testosterone). Mice in all groups except group E were administered testosterone (1 mg) subcutaneously (SC). Animals of groups B, C and D were also received topical application
Effect of Adiantum Capillus veneris Linn on an Animal Model of

of finasteride (2%), 0.5 mL vehicle, and A. capillus-veneris solution (1%), respectively, on back skin once a day for 21 days.

Qualitative evaluation of hair growth
The difference in growth of hair in each group was evaluated by visual observations and was recorded by photographs after 21 days.

Quantitative evaluation of hair growth
The skin of each animal from the dorsal area was dissected after shaving the long hair and preserved in 10% formalin. After fixation, vertical sections of the skin were prepared. The sections were stained with hematoxylin and eosin. The sections were then observed for different parameters for evaluating hair growth. The number of hair follicles in 2 mm area was recorded and reported as follicular density (number of follicles/mm). The number of follicles in anagen phase (active growth phase) and those in telogen phase (resting phase) were also counted, and anagen/telogen ratios were determined.

Statistical analysis
Data are reported as mean ± SD. Data was analyzed by one-way analysis of variance (ANOVA) followed by the Tukey’s HSD as the post hoc test. P < 0.05 was considered as significance level.

Results

Qualitative study
The animals of groups A and C showed a patch of diffuse hair loss. Loss of hair from dorsal portion of rat was clearly visible after a 21-day treatment with testosterone. After 21 days, the visual observations suggested that the animals treated with A. capillus-veneris showed less hair loss as compared to those received testosterone. The hair growth pattern in A. capillus-veneris-treated groups was comparable to that for the standard drug finasteride (Figure 1).

Quantitative study
Microscopic photograph of skin sections of animals treated with testosterone and those with testosterone plus vehicle revealed that testosterone treatment caused miniaturization of hair follicles. The follicles showed bulbous appearance and were short. The effect of testosterone on miniaturization of hair follicle was blocked by administration of topical finasteride and A. capillus-veneris in B and D animal groups, respectively (Figure 2). The histological observations showed an increase in the length as well as number of hair follicles in A. capillus-veneris-treated group. The follicular density (number of follicles/mm) was calculated. The follicular density observed in the A. capillus-veneris-treated group was 1.92 ± 0.47, whereas
catagen was included in the telogen phase when calculating anagen/telogen ratio. The number of follicles in anagen phase was considerably increased and fewer follicles in telogen phase were observed in A. capillus-veneris-treated animals. Anagen/telogen ratio was significantly affected by A. capillus-veneris, which was 1.12 ± 0.06 as against 0.23 ± 0.03 for testosterone-treated animal and 0.92 ± 0.06 for finasteride-treated animals (Table 1). The predominance of hair follicle in anagenic growth phase indicates the reversal of androgen induced hair loss in A. capillus-veneris-treated animals. As it is evident from the above data, the activity of A. capillus-veneris is comparable with finasteride.

Table 1. Follicular density and anagen/telogen ratio in sections of skin of different groups of study animals.

<table>
<thead>
<tr>
<th>Group</th>
<th>Number</th>
<th>Follicular density (no./mm), mean ± SD</th>
<th>Anagen/telogen ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>2</td>
<td>2.36 ± 0.34</td>
<td>1.35 ± 0.05</td>
</tr>
<tr>
<td>Testosterone (s.c.)</td>
<td>6</td>
<td>1.05 ± 0.21*</td>
<td>0.23 ± 0.03*</td>
</tr>
<tr>
<td>Testosterone (s.c.) + vehicle (topical)</td>
<td>6</td>
<td>1.18 ± 0.41*</td>
<td>0.25 ± 0.05*</td>
</tr>
<tr>
<td>Testosterone (s.c.) + 2% Finasteride solution (topical)</td>
<td>6</td>
<td>2.05 ± 0.49**</td>
<td>1.12 ± 0.06**</td>
</tr>
<tr>
<td>Testosterone (s.c.) + 2% A. capillus veneris Linn. sotion (topical)</td>
<td>6</td>
<td>1.92 ± 0.47**</td>
<td>0.92 ± 0.08**</td>
</tr>
</tbody>
</table>

Values represent mean±SD
* p<0.005, significance vs control
** p<0.05, significance vs testosterone (s.c.)
Discussion

Androgenetic alopecia is a heritable and androgen-dependent disorder occurs in a defined pattern. Testosterone is required, along with a genetic predisposition, for androgenetic alopecia (21). Hair follicles are the targets for androgen-stimulated hair follicle miniaturization, leading to replacement of large, pigmented hairs (terminal hairs) by barely visible, depigmented hairs (vellus hairs). The result is a progressive decline in visible scalp hair density. The current model for androgen action in the hair follicle focuses on the mesenchyme derived, regulatory dermal papilla at the base of the follicle. This responds to the circulating hormones and coordinates the rest of the follicular cells by altering the paracrine signals it produces (22).

According to our knowledge the current study is the first report on hair growth potential of *A. capillus-veneris* we have used the mouse as a model for evaluation of hair growth activity of this plant by the prepared biopsies. While new methods like trichologic follow-up, video-dermoscopy, pull test and TrichoScan are available in evaluating hair growth activity, biopsy as the oldest method is still helpful tool. Biopsy is an easy procedure, associated with little pain, providing the most anatomical and histopathological features of hair follicles (23).

Testosterone induced alopecia, was counteracted when finasteride was administered simultaneously to the mice. In hair follicles, the androgen exerts its effect either directly or after conversion by an enzyme, 5α-reductase, to dihydrotestosterone, which is a more potent androgen that binds to androgen receptors in hair follicles (24). Finasteride is an inhibitor of 5α-reductase and has been used in other testosterone-induced alopecia experiments (7-9). The alopecia was not evident in animals that were treated with *A. capillus-veneris* along with testosterone. Besides visual observation, quantitative data (follicular density and anagen/telogen ratio) also suggest inhibition of androgenic activity by *A. capillus-veneris*. Thus, *A. capillus-veneris* is considered a useful preparation for topical use in commercial formulations for androgenic alopecia and other androgen related disorders.

Phytochemical screening of *A. capillus-veneris* has revealed existence of an array of compounds including triterpenes, flavonoids, phenylpropanoids and carotenoids in this plant (25). Presence of flavonoids can provide an antioxidant activity for *A. capillus-veneris* (18). On the other hand, Kim et al. has reported that testosterone may induce hair loss by apoptosis of hair follicles rather than through the androgen metabolic pathway (26). Therefore, it could be suggested that flavonoids could participate in hair growth potential of this plant.

This preclinical study introduces an initial concept for hair growing potential of *A. capillus-veneris*. Further studies investigating antianderogenic mechanism of this plant as well as human studies will be complementary to this study.

Acknowledgement

The authors would like to thank the staff of the pharmacognosy department of the Shahid Beheshti School of Pharmacy as well as staff
of the pharmacology department of the Zanjan School of Pharmacy for their support and co-operation in this study which is a part of a Pharm.D. Thesis.

References


This article is available online at http://www.ijpr.ir